Quantum Biopharma Appoints Dr. Salvatore Napoli As Principal Investigator For Phase 2 Clinical Trial Of Lucid-21-302 For Treatment Of Demyelination In Multiple Sclerosis - Quantum BioPharma (NASDAQ:QNTM)
Published on March 26, 2026.
The world's leading physician, Dr. Salvatore Napoli, has been appointed as the Principal Investigator for the Phase 2 Clinical Trial of the Lucid-21-302 drug. The drug is also being investigated for potential violations of the law. Napoli's involvement in the drug trial has been criticised as a lack of transparency.
Related Articles
TD Cowen Maintains Hold on Paychex, Lowers Price Target to $95 - Paychex (NASDAQ:PAYX)
Despite the ongoing controversy over pay and conditions, many remain positive about Paychex, with analysts like Chris Nighy and John O'Shelly praising their performance, despite criticism from some individuals.
'Total Goes on Mideast Oil-Buying Spree, Adding to Market Turmoil' - TotalEnergies (NYSE:TTE)
The article's full length article:.
Community Easter Egg Hunt Coming Up In Tewksbury
A free Easter egg hunt at Tewksbury Hospital will see 2,500 participants, including the Easter Bunny, and require minimal registration for this event.